Ocular Therapeutix, Inc OCUL
We are an integrated biopharmaceutical company committed to redefining the retina experience. 10-K, Item 1
- Headquarters
- Bedford, MA
- CEO
- Pravin Dugel
- Next results
- around Feb 4, 2027
OCUL among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
40 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 5, 2026 against Mar 3, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Inventory growing faster than revenueInventory +17.2% ($3.0M to $3.6M) vs revenue -18.5% ($63.7M to $52.0M), +35.7 pts apart
-
Receivables -5.4% ($32.4M to $30.6M) vs revenue -18.5% ($63.7M to $52.0M), +13.1 pts apart
9 more checks with nothing to note
-
Cash from operations −$204.9M vs net income −$265.9M (FY ending Dec 31, 2025)
-
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Revenue Recognition - DEXTENZA
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
40 paragraphs in Risk Factors that were not in the 10-K filed Mar 3, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition. Income, sales, use or other tax laws, statutes, rules, or regulations could be enacted or amended at any time, which could affect our business or financial condition, including causing potentially adverse impacts…
-
Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
Additionally, although the FDA has indicated a general openness to requiring only one pivotal clinical trial for approval of a product candidate, the FDA has not yet provided specific guidance on how that approach is to be implemented. Our current plans call for the submission of an application for marketing approval of AXPAXLI for the…
-
Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
For example, following recent public statements from FDA leadership, pending the receipt of favorable topline results and planned interactions with the FDA, we intend to submit an NDA for AXPAXLI for the treatment of wet AMD based on Week 52 data from the SOL-1 trial. As the FDA has historically required two adequate and well-controlled…
-
Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
In December 2022, with the passage of FDORA, Congress required sponsors to develop and submit a diversity action plan, or DAP, for each phase 3 clinical trial or any other “pivotal study” of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $51.5M | $58.4M | $63.7M | $52.0M |
| Net income | −$71.0M | −$80.7M | −$193.5M | −$265.9M |
| Operating cash flow | −$59.6M | −$70.2M | −$134.7M | −$204.9M |
| Free cash flow | −$63.3M | −$76.3M | −$136.0M | −$216.9M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$52.0M ▼ 18.5% in FY2025−$265.9M in FY2025−$216.9M in FY2025
Recent filings
4 filings in the last 30 days · SEC EDGAR
-
8-KNov 9, 2026Quarterly results 8-K item 2.02
-
8-KNov 9, 2026Director or officer change 8-K item 5.02
-
10-QNov 9, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
Planned saleNov 5, 2026NAMRATA SAROJ (Officer) gave notice of a planned sale of 35,370 shares worth about $232K Form 144, approximate sale date Nov 5, 2026
About the company
Ocular Therapeutix, Inc, Bedford, MA · from the 10-K filed Feb 5, 2026
We are an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI, also known as OTX-TKI, our investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on our ELUTYX proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently being evaluated in a Phase 3 registrational program for wet age-related macular degeneration, or wet AMD, which we refer to as the SOL program. AXPAXLI is currently also being evaluated in a Phase 3 registrational program for diabetic retinal disease, including non-proliferative diabetic retinopathy, or NPDR, which we refer to as the HELIOS program.
- Headquarters
- Bedford, MA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 9, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 5, 2026 (open at SEC), compared with the 10-K filed Mar 3, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OCUL/export.csv") into a cell.